Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 1, 2011, Pages 5-15

  Maurer, Margarita ^a   Komina, Oxana ^a   Składanowski, Andrzej ^b   Wȩsierska Ga̧dek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Apoptosis, C 1305; Cell cycle arrest; G2 arrest; p53 tumour suppressor; Topoisomerase II

Indexed keywords

[[3(DIMETHYLAMINO)PROPYL]AMINO] 8 HYDROXY 6H V TRIAZOLO[4,5,1 DE]ACRIDIN 6 ONE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; GYRASE INHIBITOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TUMOR CELL;

ACRIDINES; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 2; FEMALE; G2 PHASE; HL-60 CELLS; HUMANS; IMMUNOBLOTTING; PHOSPHORYLATION; TOPOISOMERASE II INHIBITORS; TRIAZOLES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79251527246     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Agoff, S. N., Hou, J., Linzer, D. I., & Wu, B. (1993). Regulation of the human hsp70 promoter by p53. Science, 259(5091), 84-87.
2. Augustin, E., Mos-Rompa, A., Skwarska, A., Witkowski, J. M., & Konopa, J. (2006). Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol, 72(12), 1668-1679. (Pubitemid 44765001)
3. Bertheau, P., Espie, M., Turpin, E., Lehmann, J., Plassa, L. F., Varna, M., et al. (2008). TP53 status and response to chemotherapy in breast cancer. Pathobiology, 75(2), 132-139. (Pubitemid 351820731)
4. Borellini, F., & Glazer, R. I. (1993). Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem, 268(11), 7923-7928. (Pubitemid 23120371)
5. Bowman, K. J., Newell, D. R., Calvert, A. H., & Curtin, N. J. (2001). Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer, 84(1), 106-112.
6. Hait, W. N., & Yang, J. M. (2006). The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc, 117, 85-101; discussion 101.
7. Hande, K. R. (1998). Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta, 1400(1-3), 173-184.
8. Heisig, P. (2009). Type II topoisomerases--inhibitors, repair mechanisms and mutations. Mutagenesis, 24(6), 465-469.
9. Herceg, Z., & Wang, Z. Q. (1999). Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol Cell Biol, 19(7), 5124-5133.
10. Kusnierczyk, H., Cholody, W. M., Paradziej-Lukowicz, J., Radzikowski, C., & Konopa, J. (1994). Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp (Warsz), 42(5-6), 415-423.
11. Lemke, K., Poindessous, V., Skladanowski, A., & Larsen, A. K. (2004). The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol, 66(4), 1035-1042.
12. Lemke, K., Wojciechowski, M., Laine, W., Bailly, C., Colson, P., Baginski, M., et al. (2005). Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. Nucleic Acids Res, 33(18), 6034-6047. (Pubitemid 41742622)
13. Liu, D., Huang, C. L., Kameyama, K., Hayashi, E., Yamauchi, A., Sumitomo, S., et al. (2002). Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer, 94(8), 2239-2247.
14. Liu, L. F. (1989). DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem, 58, 351-375.
15. Mack, D. H., Vartikar, J., Pipas, J. M., & Laimins, L. A. (1993). Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 363(6426), 281-283.
16. Mroz, E. A., & Rocco, J. W. (2010). Functional p53 Status As a Biomarker for Chemotherapy Response in Oral-Cavity Cancer. J Clin Oncol.
17. Nitiss, J. L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer, 9(5), 338-350.
18. Paprskarova, M., Krystof, V., Jorda, R., Dzubak, P., Hajduch, M., Wesierska-Gadek, J., et al. (2009). Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine. J Cell Biochem, 107(3), 428-437.
19. Perrone, F., Bossi, P., Cortelazzi, B., Locati, L., Quattrone, P., Pierotti, M. A., et al. (2010). TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma. J Clin Oncol.
20. Sabisz, M., Wesierska-Gadek, J., & Skladanowski, A. (2010). Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. Biochem Pharmacol.
21. Schmid, G., Kramer, M. P., Maurer, M., Wandl, S., & Wesierska-Gadek, J. (2007). Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence. J Cell Biochem, 101(6), 1355-1369. (Pubitemid 47242768)
22. Vindelov, L. L., Christensen, I. J., & Nissen, N. I. (1983). A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 3(5), 323-327.
23. Wang, Q., Zambetti, G. P., & Suttle, D. P. (1997). Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol, 17(1), 389-397.
24. Wesierska-Gadek, J., Borza, A., Komina, O., & Maurer, M. (2009). Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential. Acta Biochim Pol, 56(3), 495-501.
25. Wesierska-Gadek, J., Schloffer, D., Gueorguieva, M., Uhl, M., & Skladanowski, A. (2004). Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res, 64(13), 4487-4497.
26. Wesierska-Gadek, J., & Schmid, G. (2000). Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem, 80(1), 85-103.
27. Wojciechowski, J., Horky, M., Gueorguieva, M., & Wesierska- Gadek, J. (2003). Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer, 106(4), 486-495. (Pubitemid 36969788)
28. Wurzer, G., Herceg, Z., & Wesierska-Gadek, J. (2000). Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res, 60(15), 4238-4244.